Turn Biotechnologies to Present Data at AACR Showing Epigenetic Reprogramming with ERA™ Technology Improves T Cell Immunotherapy

On April 18, 2023 Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines for untreatable, age-related conditions, reported immunology data that demonstrate its ERA technology enhances T cell performance against tumor cells (Press release, Turn Biotechnologies, APR 18, 2023, View Source [SID1234630281]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The findings are expected to improve the efficacy of CAR-T cell therapies.

Data will be shared at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, being held at the Orange County Convention Center in Orlando, Florida, from April 14 to 19.

The Turn Bio data will be shared on a poster, "Transient Epigenetic Reprogramming Enhances T-Cell Proliferation and Tumor Clearance," to be presented by Mustafa Turkoz, PhD, Turn Bio Immunology. An abstract of the poster was published in the AACR (Free AACR Whitepaper) journal "Cancer Research" on March 31.

Presentation details:

Title: "Transient Epigenetic Reprogramming Enhances T Cell Proliferation and Tumor Clearance".
Location: Section 23, Board number 27, in the Orange County Convention Center, during the CAR-T Cell Therapy session.
Date and Time: Tuesday, April 18, 2023, at 9 a.m. Eastern Time.
The AACR (Free AACR Whitepaper) Annual Meeting is one of the most important cancer meetings in the world, attracting key stakeholders in all areas of cancer research to connect, collaborate, and expand the frontiers of integrative cancer science and medicine. Last year’s meeting attracted more than 20,000 scientists, clinicians, other health care professionals, survivors, patients, and advocates.